Literature DB >> 11134278

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

P L Earl1, W Sugiura, D C Montefiori, C C Broder, S A Lee, C Wild, J Lifson, B Moss.   

Abstract

The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss, J. Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHIV-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134278      PMCID: PMC113961          DOI: 10.1128/JVI.75.2.645-653.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 2.  HIV vaccines--where are we going?

Authors:  C A Heilman; D Baltimore
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

Authors:  B S Graham; M J McElrath; R I Connor; D H Schwartz; G J Gorse; M C Keefer; M J Mulligan; T J Matthews; S M Wolinsky; D C Montefiori; S H Vermund; J S Lambert; L Corey; R B Belshe; R Dolin; P F Wright; B T Korber; M C Wolff; P E Fast
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

4.  Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Authors:  L Corey; M J McElrath; K Weinhold; T Matthews; D Stablein; B Graham; M Keefer; D Schwartz; G Gorse
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction.

Authors:  K Suryanarayana; T A Wiltrout; G M Vasquez; V M Hirsch; J D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

6.  Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.

Authors:  T Hanke; T J Blanchard; J Schneider; C M Hannan; M Becker; S C Gilbert; A V Hill; G L Smith; A McMichael
Journal:  Vaccine       Date:  1998-03       Impact factor: 3.641

7.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

8.  Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Authors:  D C Montefiori; K A Reimann; M S Wyand; K Manson; M G Lewis; R G Collman; J G Sodroski; D P Bolognesi; N L Letvin
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

10.  Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

Authors:  Y Lu; M S Salvato; C D Pauza; J Li; J Sodroski; K Manson; M Wyand; N Letvin; S Jenkins; N Touzjian; C Chutkowski; N Kushner; M LeFaile; L G Payne; B Roberts
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-06-01
View more
  75 in total

1.  Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.

Authors:  Francois Villinger; Ann E Mayne; Pavel Bostik; Kazuyasu Mori; Peter E Jensen; Rafi Ahmed; Aftab A Ansari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

5.  Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination.

Authors:  Lilin Wang; Dan Smith; Simona Bot; Luis Dellamary; Amy Bloom; Adrian Bot
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

7.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

8.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

9.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

10.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.